Protocatechuic acid and tanshinone IIA improve cyclophosphamide-induced immunosuppression Authors: Yejin Son, Minyeong Han, Kumju Park, Eun Hye Choi, Yoon Seok Roh Published: 2026 ABSTRACT Protocatechuic acid (PCA) and tanshinone IIA (TanIIA), the major functional constituents of Phellinus baumii (PB) and Salvia miltiorrhiza (SM), respectively, regulate innate and adaptive immune pathways and converge on nuclear factor-κB (NF-κB) signaling, providing a mechanistic basis for cooperative immune enhancement. Based on these characteristics, this study evaluated the immunomodulatory effects of a PB-SM complex and examined whether combined treatment with PCA and TanIIA could cooperatively enhance immune recovery. In a cyclophosphamide (CPA)-induced immunosuppressed mouse model, PB-SM administration significantly alleviated body weight loss and splenic atrophy and restored the reduced proportions of CD3+ T cells, CD335+/NKR-P1C+ NK cells, and F4/80+ macrophages. PB-SM also significantly improved the proliferative responses of T and B cells suppressed by CPA. At the cellular level, PB-SM enhanced phagocytic activity of macrophages and NK cell-mediated tumor killing. Consistently, PCA and TanIIA individually activated MAPK and NF-κB p65 signaling and improved macrophage functions, with the combination exhibiting enhanced activity. These findings suggest that PCA and TanIIA may contribute to immune restoration and support their combined application as a promising functional strategy for alleviating chemotherapy-induced immunosuppression. INTRODUCTION The immune system plays a central role in defending against pathogens, maintaining tissue repair, and preserving homeostasis. Dysregulation of immune function is increasingly being recognized as a major contributor to infectious diseases, metabolic disorders, and cancer, posing a substantial global health burden [1-3]. Although natural products are attracting attention as promising immunomodulators, most existing studies have focused on single compounds or isolated mechanisms, leaving the potential of complex formulations largely unexplored [4-6]. Phellinus linteus, a medicinal mushroom rich in polysaccharides and polyphenols, has been primarily linked to innate immune regulation, enhancing host defenses through TLR-mediated macrophage activation, β-glucan–induced antibody production, and reinforcement of intestinal barrier integrity [7-9]. In contrast, Salvia miltiorrhiza (Danshen), a traditional herbal medicine, exerts more pronounced effects on the adaptive immune system, stimulating T, B, and natural killer (NK) cells while engaging signaling pathways, such as PI3K/AKT, AMPK, and Nrf2 to maintain immune balance and tissue protection [10-15]. Given that innate and adaptive immunity are not independent but functionally interconnected, combining these two resources provides a rational strategy to achieve complementary and enhanced immune activation. Both ultimately converge on the nuclear factor-κB (NF-κB) signaling cascade, suggesting that their dual regulation can amplify host defense responses beyond what either agent achieves independently [16-18]. In particular, the MAPK and NF-κB pathways were prioritized as the main mechanistic focus in this study because they serve as central integration hubs for both innate and adaptive immune signals, which are known to be targeted by protocatechuic acid (PCA) and tanshinone IIA (TanIIA) individually. Although substantial evidence supports the individual efficacy of Phellinus and Salvia, investigations into their combined immunomodulatory effects remain limited, particularly under immunosuppressed conditions where reinforcement of both innate and adaptive immunity is needed. Building on this rationale, we hypothesized that a Phellinus–Salvia complex, leveraging the innate immunity-focused activity of Phellinus and the adaptive immunity-oriented effects of Salvia, could provide a more effective intervention than either alone. In this study, we demonstrate that the Phellinus–Salvia complex induces stronger immune responses than single agents, providing new evidence that plant and fungus derived bioactive compounds can complementarily strengthen host immunity. These findings highlight their therapeutic potential under immunocompromised conditions. METHODS Materials and reagents Ethanolic extracts of Phellinus baumii (PB) and Salvia miltiorrhiza (SM) were combined to formulate the PB-SM complex, which was generously provided by Pulmuone Foods Co., Ltd. The representative marker compounds, PCA (from PB) and TanIIA (from SM), were purchased from Sigma-Aldrich and used in the experiments. Dulbecco’s Modified Eagle’s Medium, fetal bovine serum, and penicillin–streptomycin solution were obtained from Corning. Cyclophosphamide (CPA) monohydrate and Concanavalin A (ConA) were also purchased from Sigma-Aldrich. The Cell Counting Kit-8 (CCK-8) was purchased from Dojindo Molecular Technologies. Enzyme-linked immunosorbent assay (ELISA) kits for mouse tumor necrosis factor-alpha (TNF-α) and interleukin (IL)-1β were part of the DuoSet ELISA Development System (R&D Systems) and were used according to the manufacturer’s instructions. Quantitative real-time polymerase chain reaction (PCR) was performed using the WizPure qPCR Master (EVA Green; W1721-8, Wizbiosolutions). Various primary antibodies for Western blotting were purchased from ABClonal. Preparation of the PB-SM extract complex The PB-SM extract complex was provided by Pulmuone Co., Ltd. Briefly, PB extract was prepared from dried fruiting bodies by aqueous extraction followed by re-extraction with 60% ethanol, after which the two extracts were combined. SM extract was prepared from roots by three consecutive extractions with 75% ethanol, and the resulting extracts were combined. Each combined extract was filtered, concentrated, and spray-dried. The PB-SM extract complex, a proprietary formulation, was prepared by combining the PB extract and SM extract at a fixed ratio and was standardized to contain PCA (0.54–0.82 mg/g) and TanIIA (6.6–9.9 mg/g). The concentrations of these marker compounds were quantified using high-performance liquid chromatography (HPLC) coupled with a UV detector, and representative HPLC chromatograms are provided in Supplementary Fig. 1. Animals and experimental design Female BALB/c mice (7 weeks old) were purchased from Samtako Bio Korea. All animal experimental procedures were approved by the Institutional Animal Care and Use Committee of Chungbuk National University (Cheongju, Korea) under Ethical Approval No. CBNUA-24-0092-01. Mice were housed under controlled environmental conditions (temperature: 25°C ± 2°C, relative humidity: 50% ± 5%, and a 12-h light-dark cycle) with free access to standard chow and water. The facility was maintained under clean conditions to prevent contamination. After a 1-week acclimation period, mice were randomly assigned to four groups: normal, model, low-dose PB-SM complex (100 mg/kg body weight), and high-dose PB-SM complex (200 mg/kg body weight). The doses of the PB-SM complex (100 and 200 mg/kg) were determined based on preliminary in vivo findings suggesting immune-enhancing potential without apparent toxicity. In addition, dose selection was supported by body surface area based human equivalent dose conversion (mouse Km = 3; human Km = 37). According to this standard conversion, mouse doses of 100 and 200 mg/kg correspond to approximately 8.1 and 16.2 mg/kg in humans, respectively. For a 60-kg adult, these values are equivalent to a daily intake of approximately 500 and 1,000 mg, which aligns with the dosage ranges typically used for functional food-derived formulations, thereby supporting the translational relevance of the selected dose levels. Based on the standardized composition of the PB-SM complex (PCA, 0.68 mg/g; TanIIA, 8.25 mg/g), the estimated in vivo intake of PCA was 0.07 and 0.14 mg/kg, and that of TanIIA was 0.83 and 1.65 mg/kg, at PB-SM doses of 100 and 200 mg/kg body weight, respectively. To induce immunosuppression, all groups except the normal group received intraperitoneal injections of CPA (100 mg/kg body weight) once daily for three consecutive days (Days 1–3). From Days 4 to 9, mice in the low-dose and high-dose groups were orally administered the PB-SM complex at 100 or 200 mg/kg body weight, respectively, once daily for six consecutive days. During the same period, mice in the normal and model groups received an equal volume of vehicle by oral gavage. On Day 10, all mice were euthanized, and blood and tissue samples were collected for subsequent analyses. Body weight and spleen index The body weight of mice was measured daily from day 0 to day 10 using an electronic balance to monitor changes during the experimental period. On day 10, the mice were euthanized, and the spleens were promptly collected and weighed. The spleen index was calculated to assess immune status using the following formula: Spleen index (%) = Spleen weight (mg) / Body weight (g). Splenic lymphocyte proliferation assay The splenic lymphocyte proliferation assay was performed as previously described, using the CCK-8 (Dojindo Laboratories) to evaluate the proliferation of T and B cells stimulated by ConA and lipopolysaccharide (LPS), respectively. Splenocytes were seeded into 96-well plates at a concentration of 2 × 10⁶ cells/ml. T cells were stimulated with ConA (5 μg/ml), and B cells were stimulated with LPS (5 μg/ml). All cultures were incubated at 37°C in a humidified atmosphere containing 5% CO₂ for 48 h. After incubation, 10 μl of CCK-8 solution was added to each well and incubated for an additional 2 h. The absorbance was measured at 450 nm using a microplate reader. The resulting absorbance values reflected the number of metabolically active cells and were used as an indicator of lymphocyte proliferation. Cell viability assay RAW264.7 cells were seeded in 96-well plates at a density of 2 × 10⁴ cells/well and incubated for 24 h at 37°C. The cells were then treated with various concentrations for 24 h. After treatment, 10 μl of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (5 mg/ml) was added to each well and incubated for 4 h. Subsequently, 150 μl of dimethylsulfoxide was added to dissolve the formazan crystals, and the absorbance was measured at 570 nm using a microplate reader. Analysis of cytokine production using ELISA RAW264.7 cells were treated with various concentrations of the indicated compounds for 24 h. After incubation, the culture supernatants were harvested and centrifuged at 1,200 × g for 10 min to remove cellular debris. The concentrations of IL-1β and TNF-α were determined using commercial ELISA kits according to the manufacturer’s protocol. Briefly, the samples were added to 96-well plates pre-coated with capture antibodies and incubated at room temperature (RT) for 2 h. After washing, biotin-conjugated detection antibodies were added and incubated for 1 h at RT. The wells were then washed thrice, followed by incubation with streptavidin–horseradish peroxidase (HRP). 3,3′,5,5′-Tetramethylbenzidine (TMB) substrate was applied for color development, and the reaction was terminated by adding a stop solution. The absorbance was measured at 450 nm using a microplate reader. Quantitative real-time PCR RAW264.7 cells were treated with various concentrations of test compounds for 6 h. Total RNA was extracted using the Hybrid-R Mini RNA Purification Kit (GeneAll Biotechnology) according to the manufacturer’s instructions. Quantitative real-time PCR was performed using the WizPure qPCR Master on a CFX Connect Real-Time PCR Detection System (Bio-Rad Laboratories). The mRNA expression levels of IL-1β, IL-6, TNF-α, and CCL2 were quantified, with GAPDH used as an internal control. NK-92 cell activation assay The cytotoxic activity of NK-92 cells against Hep3B hepatocellular carcinoma cells was evaluated using the Quanti-LDH PLUS Cytotoxicity Assay Kit (BioMAX) according to the manufacturer’s instructions. Hep3B cells were seeded into 96-well flat-bottom plates at a density of 1 × 10⁴ cells/well and incubated overnight at 37°C in a humidified atmosphere with 5% CO₂. On the following day, NK-92 effector cells were added to the wells at an effector-to-target (E:T) ratio of 15:1 and co-cultured for 4 h. After incubation, 20 μl of culture supernatant was transferred to a new 96-well plate, and 100 μl of the LDH Reaction Mixture was added to each well. The plate was incubated at RT for 30 min and protected from light. To stop the enzymatic reaction, 10 μl of stop solution was added to each well. Absorbance was measured at 450 nm using a microplate reader. Western blotting RAW264.7 cells were treated with various concentrations of test compounds for 30 min. After washing with phosphate-buffered saline (PBS), cells were lysed in radio-immunoprecipitation assay buffer supplemented with protease and phosphatase inhibitors. Protein concentrations were determined using the bicinchoninic acid assay. Equal amounts of protein were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes. Membranes were blocked with 5% skim milk in tris-buffered saline with Tween-20 for 1 h at RT, followed by overnight incubation at 4°C with primary antibodies (Abclonal; 1:1,000) against p-ERK, ERK, p-JNK, JNK, p-p38, p38, and β-actin. After washing, membranes were incubated with HRP-conjugated secondary antibodies (Thermo Fisher Scientific; 1:5,000) for 1 h at RT. Protein bands were visualized using ECL solution (GenDEPOT) and detected using the Amersham Imager 600 system (GE Healthcare). Band intensities were quantified using ImageJ software. Immunofluorescence staining of NF-κB p65 RAW264.7 cells were seeded into ibidi µ-slide eight-well chambers and treated with test compounds for 24 h. After treatment, cells were fixed with 4% paraformaldehyde for 15 min, permeabilized with 0.5% Triton X-100 for 20 min, and blocked with 5% bovine serum albumin for 30 min at RT. The cells were then incubated overnight at 4°C with a rabbit anti-phospho-NF-κB p65 antibody (1:250). After washing, cells were incubated with a fluorescein isothiocyanate-conjugated anti-rabbit IgG secondary antibody (1:1,000) for 1 h at RT in the dark. Nuclei were counterstained with 4’,6-diamidino-2-phenylindole (DAPI; 0.5 μg/ml, 3 min), and fluorescent images were captured using an inverted fluorescence microscope. Phagocytosis assay The phagocytic activity of RAW 264.7 macrophages was evaluated using a neutral red uptake assay. The cells were seeded into 96-well culture plates at a density of 1 × 10⁴ cells/well and treated with test compounds for 24 h. After treatment, the culture medium was removed, and 100 μl of 0.33% neutral red solution was added to each well and incubated for 1 h at 37°C. Following incubation, cells were washed thrice with PBS to remove excess dye. To extract the internalized dye, 100 μl of a lysis buffer (1% glacial acetic acid:ethanol = 1:1, v/v) was added, and the plate was incubated at RT for 2 h. The absorbance was measured at 540 nm using a microplate reader. Flow cytometry RAW264.7 cells (4 × 10⁵ cells/well) were seeded in six-well plates and incubated at 37°C with 5% CO₂ for 24 h. Cells were then treated with test compounds for an additional 24 h. Following treatment, cells were harvested, washed with PBS, and resuspended in fluorescence activated cell sorting (FACS) buffer. Fc receptors were blocked by incubating the cells with 2.4G2 hybridoma supernatant (1:3 dilution in FACS buffer) for 10 min at 4°C. Subsequently, cells were stained with PE-conjugated anti-mouse MHC class II antibody (clone M5/114.15.2, BioLegend; 1:100) for 20 min at 4°C in the dark. After staining, cells were washed, resuspended in 400 μl of FACS buffer, and analyzed using a flow cytometer. Hematoxylin and eosin (H&E) staining H&E staining was performed on formalin-fixed, paraffin-embedded spleen sections (4 μm). Slides were deparaffinized, rehydrated through graded ethanol, and rinsed with distilled water. Nuclear staining was performed using hematoxylin, followed by differentiation in 0.25% acid alcohol and bluing in a bluing reagent. Sections were then counterstained with eosin, dehydrated through 95% and 100% ethanol, and cleared in xylene. Finally, the slides were mounted with a xylene-compatible permanent mounting medium and allowed to dry overnight in a fume hood. All staining steps were conducted with complete immersion of tissue sections using freshly prepared reagents. Immunohistochemistry Immunohistochemical analysis was conducted on formalin-fixed, paraffin-embedded spleen sections from mice to identify immune cell markers, including CD3+ T lymphocytes, CD335+ and NKR-P1C+ NK cells, and F4/80+ macrophages. Sections (4 μm) were mounted on silane-coated slides, deparaffinized, and rehydrated. Antigen retrieval was conducted in 1:10 diluted Target Retrieval Solution (Invitrogen) at 99°C for 20 min. Endogenous peroxidase activity was blocked with 0.3% H₂O₂ in methanol. After blocking with 5% normal serum, sections were incubated overnight at 4°C with primary antibodies, followed by biotinylated secondary antibodies and VECTASTAIN ABC reagent (Vector Laboratories). 3,3′-Diaminobenzidine (DAB) was used for color development, and nuclei were counterstained with Mayer’s hematoxylin. The slides were dehydrated, cleared, and mounted for bright field microscopy. RESULTS PB-SM complex alleviates CPA-induced body weight loss, spleen atrophy, and reduced splenocyte proliferation To evaluate the immune-enhancing effects of PB-SM complex in vivo, a CPA-induced immunosuppression model was established in female BALB/c mice (Fig. 1A) [19]. Mice received intraperitoneal injections of CPA (100 mg/kg) for 3 consecutive days, followed by oral administration of PB-SM complex (100 or 200 mg/kg/day) for 6 days. Body weight was monitored throughout the experimental period. CPA treatment induced a marked and sustained decrease in body weight compared to the vehicle control, whereas PB-SM administration, particularly at 200 mg/kg, significantly attenuated this loss and promoted recovery toward baseline values (Fig. 1B, D). Morphological examination of spleens at euthanasia revealed pronounced spleen atrophy in the CPA group, while PB-SM-treated groups exhibited visibly larger spleens, suggesting mitigation of CPA-induced organ damage (Fig. 1C). Consistently, spleen weight was significantly reduced in CPA-treated mice but was partially restored by PB-SM administration (Fig. 1E). The spleen-to-body weight ratio, an indicator of immune organ status, also demonstrated a recovery trend in PB-SM groups relative to the CPA group (Fig. 1F). Functional assessment of splenocytes was conducted by measuring cell proliferation in response to mitogenic stimuli. As shown in Fig. 1G, CPA markedly suppressed both B cell proliferation (LPS stimulation) and T cell proliferation (ConA stimulation). PB-SM treatment significantly restored proliferative capacity in a dose-dependent manner, with the high-dose group approaching control levels. Overall, these findings suggest that PB-SM complex counteracts CPA-induced immune impairment by supporting spleen recovery and enhancing humoral and cellular responses. PB-SM complex protects spleen structure and restores immune cells in CPA-treated mice Histological examination of spleen sections was performed to assess the protective effects of the PB-SM complex on CPA-induced splenic damage. H&E staining revealed that the vehicle control group displayed normal splenic architecture with well-defined white and red pulp regions (Fig. 2A). In contrast, CPA-treated mice showed marked disruption of splenic architecture, including decreased lymphoid follicles and blurred boundaries between white and red pulp. PB-SM administration, particularly at 200 mg/kg, markedly restored splenic histoarchitecture toward normal morphology. To further investigate the effects of PB-SM on splenic immune cell populations, immunohistochemical staining was conducted for CD3+ T cells, CD335+ and NKR-P1C+ NK cells, and F4/80+ macrophages (Fig. 2B). CPA administration significantly reduced the density of all the immune cell markers compared to the vehicle control. Quantitative analysis confirmed that PB-SM treatment significantly increased CD335+ NK cell (Fig. 2C) and CD3+ T cell (Fig. 2D) populations, as well as NKR-P1C+ NK cells (Fig. 2E) and F4/80+ macrophages (Fig. 2F), in a dose-dependent manner. Notably, the high-dose PB-SM group restored immune cell numbers close to normal control levels. These results indicate that the PB-SM complex protects against CPA-induced histological damage in the spleen and promotes the recovery of key immune cell populations, supporting its immunorestorative potential in immunosuppressed conditions. PB-SM complex enhances NK cell cytotoxicity and macrophage immune responses The PB-SM complex was first evaluated for its effects on the viability of RAW264.7 cells using the MTT assay. Treatment with PB-SM for 24 h at concentrations up to 160 µg/ml did not significantly affect cell viability, whereas 320 µg/ml caused a marked reduction in cell viability (Fig. 3A). To assess NK cell function, NK-92 cells were co-cultured with Hep3B target cells at an E:T ratio of 15:1. PB-SM treatment markedly enhanced NK cell-mediated cytotoxicity compared with the untreated group, indicating improved NK cell-killing capacity (Fig. 3B). Macrophage activation was further examined by measuring cytokine secretion and immune-related gene expression. In RAW264.7 cells, PB-SM significantly increased TNF-α production at both 40 and 100 µg/ml, comparable to the effect of LPS stimulation (Fig. 3C). Additionally, PB-SM dose-dependently upregulated the mRNA expression of TNF-α (Fig. 3D), CCL2 (Fig. 3E), IL-1β (Fig. 3F), and IL-6 (Fig. 3G), all of which are critical mediators of inflammatory and immune responses. Overall, these findings demonstrate that the PB-SM complex can enhance NK cell cytotoxic activity and stimulate macrophage cytokine production and pro-inflammatory gene expression, supporting its potential role in immune modulation. PB-SM complex activates MAPK signaling and promotes NF-κB p65 nuclear translocation in macrophages To investigate whether PB-SM modulates inflammatory signaling pathways in macrophages, we evaluated the activation status of key MAPK and NF-κB signaling molecules. Western blot analysis revealed that treatment with PB-SM at 40 and 80 μg/ml increased the phosphorylation of ERK, JNK, and p38 compared with the control group, indicating activation of MAPK-related signaling (Fig. 4A–D). Notably, the phosphorylation levels were comparable to those observed in the LPS-treated positive control group, suggesting engagement of immune-related signaling pathways rather than direct pro-inflammatory mimicry. Immunofluorescence staining demonstrated that PB-SM promoted nuclear translocation of NF-κB p65, as evidenced by increased co-localization of p65 with DAPI-stained nuclei (Fig. 4E). Quantitative analysis showed a higher percentage of p65-positive nuclei in PB-SM–treated cells relative to controls, with patterns similar to those induced by LPS (Fig. 4F). These findings indicate that the PB-SM complex is associated with activation of MAPK signaling and NF-κB p65 nuclear translocation, consistent with macrophage immune activation. PB-SM complex and its constituents enhance macrophage phagocytic activity and MHC class II expression To investigate whether PB-SM enhances macrophage effector functions, both phagocytic activity and MHC class II expression were evaluated. Phagocytic activity was assessed using the neutral red uptake assay in RAW264.7 macrophages treated with PB-SM (40 and 80 μg/ml) for 24 h. As shown in Fig. 5A, B, PB-SM treatment significantly increased the phagocytic index compared with the control group with effects comparable to those of LPS stimulation, indicating enhanced macrophage phagocytic capacity. Flow cytometric analysis further demonstrated a concentration-dependent increase in mean fluorescence intensity (MFI) of MHC class II following PB-SM treatment, similar to the LPS group (Fig. 5C–E). These findings suggest that the PB-SM complex activates macrophages by enhancing both phagocytic function and immune-related surface marker expression. PCA and TanIIA promote macrophage activation and NK cytotoxicity without cytotoxic effects To compare the immunostimulatory activity of the PB-SM complex with its individual marker compounds, PCA from PB and TanIIA from SM were evaluated in NK and macrophage functional assays. In NK-92 cytotoxicity assays against Hep3B target cells, the PB-SM complex (30 μM total) markedly enhanced NK cell-mediated killing, whereas PCA (25 μM) and TanIIA (5 μM) alone showed smaller or insignificant effects (Fig. 6C), without cytotoxicity in RAW264.7 macrophages (Fig. 6A, B). To examine macrophage activation, cytokine production was evaluated at both protein and transcriptional levels. ELISA revealed that PCA and TanIIA significantly increased TNF-α secretion compared with the control, and the PB-SM complex further amplified this effect (Fig. 6D). Consistently, RT-qPCR analysis demonstrated that the mRNA expressions of TNF-α, IL-1β, and IL-6 were significantly upregulated by PCA and TanIIA, with the complex group again displaying the strongest induction (Fig. 6E–G). Collectively, these results indicate that the PB-SM complex exerts additive immunostimulatory effects, enhancing NK cell cytotoxicity and promoting macrophage pro-inflammatory activation beyond the activity of its individual marker compounds. PCA and TanIIA activate MAPK and NF-κB signaling similarly to PB-SM complex To determine whether PCA and TanIIA activate MAPK and NF-κB signaling pathways similarly to PB-SM, Western blotting and immunofluorescence analyses were performed. Western blot results showed that both PCA (25 μM) and TanIIA (5 μM) individually enhanced the phosphorylation levels of ERK, JNK, and p38. Notably, the combination treatment (Complex 30 μM) induced a more pronounced activation compared to single agent treatments (Fig. 7A–D). Quantitative analysis of the phosphorylation ratios (p-ERK/ERK, p-JNK/JNK, and p-p38/p38) confirmed statistically significant increases in the complex group (p < 0.01–0.0001). To assess NF-κB pathway activation, nuclear translocation of p65 was visualized by immunofluorescence staining. The proportion of p65-positive nuclei increased markedly in both the PCA and TanIIA groups, with the highest nuclear localization observed in the complex group comparable to that of the LPS-treated positive control (Fig. 7E, F). These results suggest that co-administration of PCA and TanIIA is associated with enhanced MAPK and NF-κB pathway activation. PCA and TanIIA enhance macrophage phagocytosis and MHC class II expression To evaluate the effects of PCA, TanIIA, and their combination (Complex) on macrophage effector functions, phagocytic activity and MHC class II expression were measured in RAW264.7 cells. Phagocytosis was assessed using the neutral red uptake assay. All treatment groups showed significantly higher phagocytic indices compared with the control, with the complex group displaying the strongest enhancement, similar to LPS stimulation (Fig. 8A, B). Flow cytometry analysis revealed that PCA, TanIIA, and the complex all increased the surface expression of MHC class II molecules compared to the control group (Fig. 8C–E). Quantitative MFI data indicated that the complex elicited a greater upregulation than either compound alone, suggesting additive effects. These results indicate that PCA and TanIIA can potentiate macrophage-mediated immune functions, with the combined PB-SM complex exerting the most pronounced enhancement of both phagocytic capacity and antigen-presentation related marker expression. DISCUSSION Chemotherapy eliminates malignant cells but simultaneously suppresses host immunity, thereby limiting its therapeutic efficacy. Among chemotherapeutic agents, CPA is widely used as an antitumor drug and a classical immunosuppressant. However, treatment with CPA often leads to severe lymphopenia, T-cell exhaustion, and impaired macrophage function, which collectively disturb immune homeostasis and increase the risk of infection during cancer therapy [20-22]. Thus, chemotherapy-induced immunosuppression represents a major obstacle to successful cancer treatment, highlighting the need to develop adjuvant strategies capable of protecting or restoring immune competence. In this study, we investigated the immunomodulatory potential of the PB-SM complex using a CPA-induced immunosuppressed mouse model. We aimed to evaluate whether PB-SM could serve as a natural immunoprotective agent capable of mitigating chemotherapy-associated immune dysfunction and maintaining immune balance during treatment. PB primarily strengthens innate immunity through its polysaccharides and phenolic compounds. In this study, PB treatment significantly promoted macrophage activation and increased the production of proinflammatory cytokines, including IL-1β, IL-6, and TNF-α. PCA, a major active component, enhanced phagocytic activity in vitro and activated MAPK and NF-κB signaling pathways in RAW264.7 macrophages, exhibiting similar immune stimulatory effects [23-25]. These results suggest that PCA may act as an important contributor to PB-induced macrophage activation and cytokine regulation and may play a role in the early phase of immune restoration. In contrast, Salvia miltiorrhiza (Danshen) may contribute to adaptive immune modulation. Its lipophilic compound, TanIIA, has been reported to enhance NK-cell cytotoxicity and macrophage-associated cytokine responses. In the present study, co-administration of PCA and TanIIA was associated with increased activation of MAPK and NF-κB signaling and elevated cytokine production. These complementary actions may contribute to the enhanced immunomodulatory effects observed with the PB-SM combination compared with individual components [25-27]. In these mechanistic experiments, the concentrations of PCA (25 μM) and TanIIA (5 μM) were selected within commonly reported effective ranges to allow pathway activation to be evaluated without excessive stimulation or cytotoxic stress. The 5:1 ratio was chosen to approximate the proportional balance of these marker compounds in the standardized PB-SM extract. This design was intended to maintain biological relevance to the intrinsic composition of the complex and to facilitate mechanistic interpretation of PB-SM–mediated immune activation. The immunomodulatory activities of fungal polysaccharides are generally initiated through their recognition by pattern recognition receptors (PRRs) expressed on innate immune cells. Among these receptors, Toll-like receptor 4 (TLR4) has been widely reported as an important mediator of immune activation by Phellinus-derived polysaccharides, which activate both MyD88- and TRIF-dependent signaling pathways leading to cytokine production [26]. In addition, other PRRs, including TLR2 and C-type lectin receptors such as Dectin-1, may cooperatively recognize structurally complex components of the PB-SM complex, potentially contributing to downstream MAPK and NF-κB signaling consistent with our observations [27]. Although receptor-specific validation using pharmacological inhibitors (e.g., TAK-242) or knockdown models was not performed in the present study, the observed immune-enhancing effects are consistent with established PRR-mediated mechanisms reported for Phellinus-derived polysaccharides [8]. Importantly, although PB-SM and its constituents activated MAPK and NF-κB pathways in a manner comparable to LPS in vitro, activation of these signaling pathways does not necessarily indicate pathological hyperinflammation. MAPK and NF-κB pathways represent common upstream mechanisms involved in innate immune activation and immune restoration. In the present study, PB-SM was evaluated under CPA-induced immunosuppressive conditions, where the primary objective was to restore impaired immune competence rather than to induce excessive inflammatory responses. Notably, no overt toxicity or signs of uncontrolled inflammation were observed at the administered doses. Moreover, previous studies have demonstrated that PCA and TanIIA can exert inflammation-limiting or anti-inflammatory effects by suppressing excessive LPS-induced TLR4/NF-κB/MAPK activation and pro-inflammatory mediator production, supporting the interpretation that PB-SM induces a controlled immunostimulatory response rather than pathological inflammation [25,28]. Overall, our findings suggest that the PB-SM complex exerts integrated immunomodulatory effects by supporting both innate and adaptive immune responses. PB-SM partially restored impaired immune homeostasis under CPA-induced immunosuppressive conditions through activation of the MAPK and NF-κB signaling pathways, resulting in enhanced macrophage function, increased NK-cell cytotoxicity, and improved lymphocyte proliferation. Compared with single-extract treatments, the combined formulation exhibited enhanced immunostimulatory efficacy, supporting the concept that multicomponent herbal formulations can achieve broader immune activation through pathway crosstalk and mutual reinforcement. Despite these promising findings, the present study primarily focused on cellular and molecular mechanisms, and additional in vivo and clinical studies are warranted to further validate the immunomodulatory efficacy of PB-SM. In particular, investigations into receptor-level interactions, signaling pathway crosstalk, and functional interactions among key active constituents would provide deeper mechanistic insights and help establish a comprehensive scientific foundation for the potential application of PB-SM as a natural immunotherapeutic adjuvant in immunosuppressed conditions. In addition, a limitation of the present study is that the individual or combined effects of the major marker compounds, PCA and TanIIA, were not directly evaluated in vivo in the CPA-induced immunosuppression model. The current study was designed to assess the immunomodulatory efficacy of the standardized PB-SM complex as a whole, rather than to dissect the in vivo contributions of individual constituents. Accordingly, PCA and TanIIA were examined in vitro as representative marker compounds to support mechanistic interpretation, based on extensive prior literature reporting their immunomodulatory and inflammation-limiting activities. Further in vivo studies using purified compounds or defined combinations will be necessary to clarify the specific contributions of PCA and TanIIA to the observed in vivo effects of PB-SM. SUPPLEMENTARY MATERIALS Supplementary data including one figure can be found with this article online at https://doi.org/10.4196/kjpp.26.004